
 
  


BLA 125197 Provenge - Provenge, March 7, 2010




 
From:             Greeley, George
Sent:                Sunday, March 07, 2010 1:45 PM
To:                    Tull, Lori
Cc:                    Stowe, Ginneh D.
Subject:           BLA 125197 Provenge
Importance:    High
 

Hi Lori,

The Provenge (sipuleucel-T) full waiver was reviewed by the PeRC PREA 
Subcommittee on January 27, 2010. 

The Division recommended a full waiver because disease/condition does not exist 
in children.   

The PeRC agreed with the Division to grant a full waiver for this product.

Thank you.

George Greeley
Regulatory Health Project Manager
Pediatric and Maternal Health Staff
FDA/CDER/OND
10903 New Hampshire Avenue
Bldg. 22, Room 6467
Silver Spring, MD 20993-0002
Phone: 301.796.4025
Email: george.greeley@fda.hhs.gov
Please consider the environment before printing this e-mail.
 



  Consumer Updates


  About FDA


  Contact FDA


  Browse by Product Area


  Product Areas

  back

    Food


    Drugs


    Medical Devices


    Radiation-Emitting Products


    Vaccines, Blood & Biologics


    Animal & Veterinary


    Cosmetics


    Tobacco Products


 